Targeted pre-launch scientific outreach drives 40% faster treatment adoption

New veeva pulse findings show congresses and early-career experts have the strongest influence on patient outcomes pleasanton, calif. , july 25, 2024 /prnewswire/ -- veeva systems (nyse: veev) today revealed that targeted pre-launch scientific outreach maximizes medical affairs teams' impact on treatment adoption in the latest veeva pulse field trends report.
VEEV Ratings Summary
VEEV Quant Ranking